2025 Partners
Program Partner
Adimab
Adimab is the most successful antibody discovery company in the industry, with 450+ discovery campaigns and 55+ clinical programs created with more than 100 partners. Our unique, yeast-based platform is a comprehensive and effective tool for the discovery and optimization of fully human monoclonal and bispecific antibodies. Our partners range from some of the biggest pharma to biotech companies at all stages to leading academic institutions. We’re committed to staying at the cutting edge
of protein-based therapeutic discovery to enable the highest quality IgGs, multispecifics, CARs and other modalities to allow our partners to have the most successful therapeutic programs possible.
Program Partner
Alloy Therapeutics
Alloy Therapeutics accelerates the drug discovery process by providing access to best-in-class foundational drug discovery platforms, services, and company creation capabilities. Alloy Therapeutics has developed novel strains for fully human antibody discovery and created innovative technology to support a multitude of modalities that can help to quickly identify candidates. Leveraging our world class scientists, Alloy therapeutics platforms and services enables you to build a more robust antibody-based therapeutic pipeline.
Hosting Partner
Miltenyi Biotec
Miltenyi Biotec is a global leader in innovating technologies and services for patient-specific cell and gene therapies, transforming scientific discoveries into practical treatments for personalized medicine. With over 35 years of expertise, it supports biomedical discoveries and translates them into clinical applications, enhancing patient access to new therapies. Miltenyi Biotec focuses on offering integrated solutions for complex challenges in treating cancers, autoimmune diseases, and inherited disorders. Its Miltenyi Bioindustry division provides expert guidance to therapy developers efficiently from process development to commercialization. Headquartered in Bergisch Gladbach, it employs 4,900 people across 24 countries.
Exhibition Partner
Promega
We share your passion for science. Promega is a global leader in providing innovative solutions and technical support to life scientists in academic, industrial, and government settings. Promega products are used by life scientists who are asking fundamental questions about biological processes as well as by scientists who are applying scientific knowledge to diagnose and treat diseases, discover new therapeutics, and use genetics and DNA testing for human identification. Let’s collaborate.
Exhibition Partner
Alithea Biotechnology GmbH
Alithea Biotechnology GmbH (GER) is providing cutting-edge HLA peptidomics technologies for target discovery, validation and off-target toxicity profiling since 2019. Alithea has a web-accessible quantitative HLA peptide database, HLA-Compass, allowing to navigate peptide presentation in health and cancer. Proprietary HLA peptide binding predictors and strong experience in the quantification of HLA ligands together with most sensitive timsToF Ultra-powered mass spectrometry equipment facilitate high quality and sensitivity. Proteogenomics capabilities and an in-house repository of HLA typed tissue samples facilitate rapid validation of hypotheses for TCR/TCRm drug discovery. Alithea happily supports you in solving RnD challenges from target discovery to IND submission.
Exhibition Partner
Biocentriq
BioCentriq is a highly versatile clinical-phase cell therapy contract development and manufacturing organization (CDMO). It has been successfully developing, manufacturing, and releasing GMP autologous and allogeneic cell therapies for clinical trials from 2022. BioCentriq is known for its high level of experience across the organization as a specialist CDMO. It specifically specializes in early and mid-stage cell therapies. BioCentriq is comprised of highly experienced and industry-recognized leadership, scientists, engineers, analysts, and manufacturing specialists. BioCentriq utilizes state-of-the-art quality systems, infrastructure, and digitalized processes. Its LEAP™ Advanced Therapy Platform has been designed to reduce manufacturing initiation timelines by over 50% from industry average. BioCentriq adds additional resources with the backing of Green Cross of South Korea, a global leader in the pharmaceutical and biotechnology sectors, as its majority shareholder, acquired for $73 million in May 2022.
Exhibition Partner
BPS Bioscience
BPS Bioscience strives to advance new scientific discoveries that lead to therapies by creating innovative research solutions. We drive advancements across a broad range of critical research areas, providing 4500+ recombinant cell lines, virus-based tools, proteins, biochemical and cell-based assay kits, and compound screening focused on drug discovery.
Innovation Partner
BioMedX
BioMed X is an independent research institute with locations in Heidelberg, Germany, New Haven, and an open innovation incubator at Boehringer Ingelheim's R&D campus in Ridgefield, Connecticut, along with a global partner network. At the intersection of academia and industry, we drive pioneering research in oncology, immunology, neuroscience, platform technologies, and artificial intelligence. Supported by leading pharmaceutical companies, our projects are led by early-career scientists recruited from top institutions worldwide. Through global crowdsourcing and local incubation, we tackle major biomedical R&D challenges. With a focus on curiosity-driven exploration and rigorous validation, we advance translational biomedicine and foster cross-disciplinary innovation. Our research has also resulted in the development of new technologies for the pharmaceutical and biotech industries, such as T-Finder.